title: Metoclopramide in the treatment of reflux oesophagitis: a comparison of normal and controlled-release formulations.
abstract: Twenty patients with reflux oesophagitis were recruited into a randomized, single (investigator)-blind, two-part crossover study of controlled-release metoclopramide ('Gastrobid Continus' tablets) 15 mg given twice daily, and normal-release metoclopramide ('Maxolon'), 10 mg given 4-times daily. Both treatment regimens were efficacious in reducing the severity of heartburn, the incidence of waking at night due to pain from heartburn and the severity of gastro-intestinal symptoms. The incidence of volunteered and sought side-effects/symptoms was similar on both treatments. More patients preferred the controlled-release than the normal-release formulation. It is concluded that 15 mg controlled-release metoclopramide twice daily and 10 mg normal-release metoclopramide 4-times daily are equally effective and well-tolerated treatment regimens, but that the controlled-release formulation has the advantage of a smaller dose and twice daily administration.
authors.affiliation: Mater Infirmorum Hospital, Belfast, Northern Ireland.
authors.forename: J
authors.initials: J
authors.lastname: McLoughlin
authors.forename: A J
authors.initials: AJ
authors.lastname: Miller
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D003692:Delayed-Action Preparations; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D017060:Patient Satisfaction; D012720:Severity of Illness Index; D016037:Single-Blind Method; D014851:Wakefulness
chemical_list: D003692:Delayed-Action Preparations; D008787:Metoclopramide